Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.
- DOI
- 10.1080/14796694.2026.2688570
- Published
- 2026 Jul
- Container
- Future oncology (London, England)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14796694.2026.2688570,
title = {Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.},
author = {Siu DHW and Lin FPY and Thomas DM and Thavaneswaran S and Espinoza D and Chinchen S and Ballinger ML and Simes RJ and Lee CK},
year = {2026},
journal = {Future oncology (London, England)},
doi = {10.1080/14796694.2026.2688570},
url = {https://doi.org/10.1080/14796694.2026.2688570}
}RIS
TY - JOUR TI - Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program. AU - Siu DHW AU - Lin FPY AU - Thomas DM AU - Thavaneswaran S AU - Espinoza D AU - Chinchen S AU - Ballinger ML AU - Simes RJ AU - Lee CK PY - 2026 JO - Future oncology (London, England) DO - 10.1080/14796694.2026.2688570 UR - https://doi.org/10.1080/14796694.2026.2688570 ER -
APA
DHW, S., FPY, L., DM, T., S, T., D, E., S, C., ML, B., RJ, S., & CK, L. (2026). Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST program.. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2688570
Source records
- pubmed · retrieved 2026-09-26T09:19:07.998Z